Boston Scientific Acquires Nalu Medical for $533 Million

Boston Scientific Corporation announced a definitive agreement to acquire Nalu Medical, Inc., a privately held medtech company that develops minimally invasive solutions for chronic pain management. Boston Scientific has been a strategic investor in Nalu Medical since 2017.

The deal provides for an upfront cash payment of approximately $533 million for the equity not already owned by Boston Scientific. On a 100% basis, and prior to considering Boston Scientific's existing equity and other closing adjustments, the total transaction value is $600 million.

Nalu Medical’s groundbreaking Nalu Neurostimulation System offers targeted relief for adult patients suffering from severe, intractable chronic pain of peripheral nerve origin, such as the shoulder, lower back, and knee, through peripheral nerve stimulation (PNS).

The system uses light electrical impulses to block the pain signals on their way to the brain and has a small, battery-free implantable pulse generator that is powered wirelessly by an external therapy disc, controllable via a smartphone app.

The Nalu system was granted FDA 510(k) clearance in 2019. In the COMFORT and COMFORT 2 clinical trials, the system showed significant and lasting pain relief with 87% of the patients reporting a pain reduction of more than 50% at 12 months and real-world data reporting 94% of the patients realizing clinically significant improvement.

Also Read: Shalby Hospitals Announces Major City Expansion

Jim Cassidy, President Neuromodulation at Boston Scientific, said that the acquisition is a good fit with Boston Scientific's existing therapy portfolio, including spinal cord stimulation and radiofrequency ablation, and extends the company's advanced pain relief offering.

The deal is scheduled to be completed by the first half of 2026. Nalu is expected to record sales of more than $60 million in 2025 and a year-over-year growth of around 25% in 2026. In 2027, the transaction is expected to be slightly beneficial to adjusted EPS and the benefit will be increasing thereafter.